INTRODUCTION
============

Cardiovascular disease (CVD) is a global major health problem and has remained a leading cause of death, despite the advances in the current medical technologies ([@ref1]). Cardiovascular regeneration (CVR) with adult stem-cell (ASC) therapy is a promising field for addressing advanced CVD ([@ref2], [@ref3]). Although there are diverse origins of ASCs, the cells that are mostly studied for CVR are mesenchymal stem cells (MSCs) and cardiac stem cells ([@ref4]). Given the salutary effects of the ASCs for CVD reported by previous studies, there have been many preclinical studies as well as clinical trials conducted with the ASCs ([@ref4], [@ref5]).

The putative 'cardiac stem/progenitor cell (CS/CPC)' is also called a cardiac mesenchymal stem cell, cardiac interstitial cell, cardiac mesenchymal stromal cell (CMSC), or cardiosphere-derived cell (CDC). These cells are usually obtained from the right ventricular septum through cardiac biopsy, or from a left atrial sample of cardiac surgery ([@ref6], [@ref7]). In particular, CDCs indicate the cells derived from cardiospheres; multicellular clusters formed from the primary culture of cardiac specimen. There are several issues about CVR using different types of CS/CPCs. Especially, based on the research that c-kit^＋^ cells were potential CS/CPCs for rejuvenating heart muscles in mice ([@ref8]), many researchers had considered these cells to be CS/CPCs. However, recent studies have proved that c-kit^＋^ cells are only a small proportion of CDCs, have low regenerative potential, and originate from cardiac endothelial cells, rather than from CS/CPCs ([@ref9], [@ref10]). Another issue is about CD90, which was originally discovered as a thymocyte antigen (thy-1) and can be used as a marker for a variety of stem cells and fibroblasts. Despite limited information regarding CD90 in CVR, several studies proved that CD90^−^ CPCs expressed the genes related to stemness and could differentiate into mature cardiomyocytes with complete sarcomere formation ([@ref9], [@ref11], [@ref12]). Although these cells also showed a greater regenerative potential in myocardial infarction (MI), it is still unclear which types of CS/CPCs are more important to the CVR.

Recently, another important concept has been receiving attention in ASC therapy; the paracrine effect. Many studies showed that the cardiac functional advances were not the direct effects of the transplanted CS/CPCs themselves. Instead, such improvement seemed to be induced by means of paracrine factors ([@ref13], [@ref14]); the extracellular vesicle (EV) is one strong candidate ([@ref15]-[@ref17]). EVs, also known as exosomes, are nanosized vesicles encompassed by lipid bilayer with diameters from 30-130 nm. EVs exist in almost all biological fluids, including blood, urine, and cell culture medium. They are released from the cells when multivesicular bodies fuse with the cell membrane. They participate as cellular cargos by carrying genetic materials and proteins, facilitate intercellular communication ([@ref16]), and have specificity that depends on their originating cells ([@ref15]). EVs from CDCs could inhibit apoptosis, promote proliferation of cardiomyocytes, and improve cardiac functions in MI mouse models by means of some miRNAs ([@ref18], [@ref19]).

In this study, we first compared the characterization of h-CMSCs and h-BM-MSCs, and identified EVs from the media of the cells. Relatively few studies have compared the effects of these cells directly ([@ref20]-[@ref22]), and especially CD90^low^, c-kit^negative^ CS/CPCs need to be further investigated. To compare the effects of EVs from each cell group, we evaluated *in vitro* effects of EVs on angiogenesis. Therefore, the comparative studies regarding EVs of h-BM-MSCs and h-CMSCs with normoxic and hypoxic conditions would help decide on future effective therapeutic target.

RESULTS
=======

Characterization of h-BM-MSCs and h-CMSCs
-----------------------------------------

To characterize the cultured h-BM-MSCs and h-CMSCs, we analyzed various cell surface markers for hematopoietic or cardiac cells by flow cytometry ([Fig. 1A](#F1){ref-type="fig"}). Expression of a cluster of differentiation (CD)45, a type I transmembrane protein that is present in various isoforms on differentiated hematopoietic cells, is less than 1% in both cell populations. Another hematopoietic stem-cell marker, CD34, is expressed only 1.87% in CMSCs and 6.09% in BM-MSCs, which meant that these cells are a CD45 and CD34 negative cell population, as previously reported ([@ref23]). Importantly, CD90 is differently expressed in each cell population; 82.1% of BM-MSCs vs. 26.3% of CMSCs, which is similar to CDCs described ([@ref22]). Both BM-MSCs and CMSCs express CD105 in about 80% of the cell population. CD105 (Endoglin), a membrane glycoprotein and a part of the TGF β receptor complex, plays a critical role in neoangiogenesis. CD117, known also as c-kit, is a stem-cell growth factor receptor on the surface of hematopoietic stem cells and some cancer cells. Expression levels of CD117 are less than 1% in both cell groups.

To further define the characteristics of the cells, we did RT-PCR assays for various marker genes. NANOG and SOX2, the transcriptional factors of embryonic stem cells, were expressed in all three cell populations ([Fig. 1B](#F1){ref-type="fig"}). For cardiac markers, mRNAs of NKX2-5 and myosin heavy chain, the α isoform (MYH6), were not noticeable in all groups, but the expression of GATA4, a cardiac-specific transcription factor for proper mammalian cardiac development, was prominent in CMSCs but not in BM-MSCs ([Fig. 1B](#F1){ref-type="fig"}). GATA4 and NKX2-5 are early markers of precardiac cells and present synergism as cofactors ([@ref24]). GATA4 is expressed in CS/CPCs followed by the expression of NKX2-5 and ISL1 of the cardiac mesoderm.

Characterization of EVs isolated from CMSCs and BM-MSCs
-------------------------------------------------------

EVs were isolated from conditioned media from each cell population. Transmission electron microscopy showed that EVs exhibited umbilicated round morphologies ([Fig. 2A](#F2){ref-type="fig"}). Size measurements by dynamic light-scattering (DLS) analysis found a size of 95-115 nm for EVs ([Fig. 2B](#F2){ref-type="fig"}). CMSC-Hpx EVs are slightly larger than the EVs from normoxia-conditioned CMSCs (CMSC-Nx) ([Fig. 2A, B](#F2){ref-type="fig"}), which was similar to a previous report ([@ref21]). Nanoparticle tracking analysis (NTA) confirmed the size distribution of EVs and showed sufficient particle concentration ([Fig. 2C](#F2){ref-type="fig"}). The purities of isolated EVs were analyzed by a size exclusion chromatography with high-performance liquid chromatography (HPLC) system, which exhibited levels of contaminating substances smaller than EVs were less than 5% in all EV preparations ([Fig. 3A](#F3){ref-type="fig"}). Immunoblotting analysis have shown the enrichment of EV surface markers tetraspanins (CD9, CD63, and CD81) with minor differences at expression levels ([Fig. 3B](#F3){ref-type="fig"}), while H2B histone, one of common contaminants in EV preparation was not detected in all isolated EVs used in this study ([Fig. 3B](#F3){ref-type="fig"}).

CMSC-Hpx EVs exhibit functional superiority on *in vitro* angiogenesis
----------------------------------------------------------------------

To evaluate the effects of EVs on angiogenesis, we did a tube-formation assay with HUVECs (human umbilical vein endothelial cells). HUVECs were cultured with hVEGF (positive control), BM-MSC EVs, CMSC-Nx EVs, or CMSC-Hpx EVs, and these were compared with the cells with media only (negative control; NC). HUVECs treated with BM-MSC EVs and CMSC-Hpx EVs showed tube formation significantly better than did HUVECs with NC at 6 h ([Fig. 4](#F4){ref-type="fig"}), whereas CMSC-Nx EVs failed to demonstrate superiority over NC in tube formation. The formation of tube-like structures was increased with time up to 6 h in all groups of experiments. Interestingly, the tube-like structures lasted for 8 h in the cells treated with VEGF or CMSC-Hpx, whereas these structures started to collapse around 8 h in the group of BM-MSC EVs ([Fig. 4B, C](#F4){ref-type="fig"}). With our results, CMSC-Nx EVs did not show improvement in tube formation, and only CMSC-Hpx EVs were able to improve the tube formation, creating tube-like structures that persisted for 8 h, all of which were comparable to the effect of VEGF.

DISCUSSION
==========

We used the CMSCs obtained by *ex vivo* expansion of human heart tissue using 3D culture as previously described ([@ref25]). These CMSCs did not form cardiospheres, but shared similar phenotypes with CDCs of CD90^low^, c-kit^negative^, CD105^positive^. The CMSCs were distinguished from MSCs in the expression of CD90 ([@ref22]).

Recently, a decision has been made on an issue concerning the regeneration of CS/CPCs, especially c-kit^＋^ cells ([@ref6], [@ref8], [@ref26]): 31 papers from a researcher at the Harvard lab studying the role of c-kit^＋^ cells as potential CS/CPCs were retracted because of 'the inclusion of fabricated and/or falsified data' and the ongoing clinical trials involving these cells were paused ([@ref27], [@ref28]). Many scientists say that it is time to reset the putative CS/CPC research, although there are some researchers saying that c-kit^＋^ cells are still valid for further analysis of regeneration effects based on some animal study results ([@ref28], [@ref29]). However, it was known that c-kit^＋^ cells are only a minor fraction of the whole CDC from previous reports ([@ref22]), and these cells barely differentiate into cardiomyocytes. Moreover, the remnant c-kit^＋^ cells in the heart are regarded as cardiac endothelial cells rather than as CS/CPCs ([@ref30]). Retrospective analysis of a recently completed clinical trial (CADUCEUS) demonstrated that c-kit expression was not related to the therapeutic effect of CDCs in humans, and that c-kit^＋^ cells were functionally inferior to unsorted human CDCs ([@ref9]). Given these previous studies, our study tested the idea that CS/CPCs with low c-kit expression may secrete paracrine factors by means of EVs to promote angiogenesis. In our study, both BM-MSCs and CMSCs hardly expressed c-kit.

Meanwhile, CMSCs and BM-MSCs are distinguished by CD90 expression, and unlike BM-MSCs, CMSCs expressed only 26% of CD90. Li *et al*. also reported a similar profile of gene expression: the expression of CD90 as 18.4% in CDCs, compared with an expression of 99.0% in BM-MSCs ([@ref22]). Thy-1 knock-out mice are viable and grossly normal ([@ref31]), and the definite roles of CD90^−^ clones in CVR are not clear, but some researchers reported data regarding this topic. They demonstrated the superiority of CD90^−^ CDCs over CD90^＋^ CDCs ([@ref9], [@ref11], [@ref12]). In the chronic MI rat model, injection of CD90^−^ CMSCs augmented cardiac function outperforming CD90^＋^ cells, and histological analysis of CD90^−^ cells revealed an increase in vascularization within the infarct lesion ([@ref12]). Other studies reported similar salutary effects, since CD90^−^ cells secret less inflammatory cytokines and may differentiate into cardiomyocytes ([@ref9]). Interestingly, CD90^−^ cells expressed significantly more hepatocyte growth factor (HGF) than did CD90^＋^ cells, and both CD90^−^ and CD90^＋^ CMSCs secrete VEGF or basic fibroblast growth factor (bFGF) comparably ([@ref12]).

By means of the transcriptional profiles and gene ontology enrichment analysis of adult human CDCs subdivided by the expression of CD90, CD90^−^ clones were enriched with the genes related to stemness, whereas CD90^＋^ clones were enriched with fibroblast-associated genes ([@ref11]). Two separate studies found that the expression level of CD90/THY-1 changes dynamically at the formation of cardiospheres under different culture conditions ([@ref11], [@ref32]). Our CMSCs were isolated as CD90^low^ CS/CPCs under specific culture condition to promote stemness ([@ref25]).

Hence, our CD90^low^c-kit^negative^CD105^positive^ CMSCs are likely to play a significant role in the regeneration of the heart as an active fraction. Most research with CS/CPCs has been done with CDCs of heterogeneous populations or with c-kit^＋^ cells, so far. Therefore, further studies with c-kit^negative^ and CD90^negative^ clones are needed to reveal the more effective therapeutic application of CS/CPC and would be helpful for understanding the roles of these cells.

GATA4 is one of the earliest transcription factors and a critical regulator of cardiac development, and interacts with many transcriptional factors, such as NKX2-5 ([@ref33], [@ref34]). Although GATA4 is crucial for regulating the expression of NKX2-5, it has been proposed that additional signaling pathways are needed for the initial activation of NKX2-5 ([@ref34], [@ref35]). In our results, CMSCs expressed only GATA4, but not NKX2-5. Other studies using CS/CPCs from rotating tissue-culture conditions similar to our work, have also reported that GATA4 is expressed with limited expression of NKX2-5, which proposed these cells in early developmental stages ([@ref11], [@ref36]). Therefore, our cells may also be considered to be in early developmental stages before expressing NKX2-5, and further analysis will help us understand the roles of CS/CPCs at various developmental stages or marking various kinds of stemness during primary culture.

Our results showed that CMSC-Hpx EVs improved tube formation, but CMSC-Nx EVs did not. EV release from hypoxic MSCs was associated with an increased hypoxia-inducible factor 1-alpha activation, which could increase angiogenesis through Jagged-1 ([@ref37], [@ref38]). Hypoxia-treated EVs from human adipose-derived MSCs were reported to activate the protein kinase A signaling pathway and promote the expression of VEGF ([@ref20]). EVs from hypoxic CDCs (CD90^high^ cells) were reported to contain the increased level of EV-assocoated miRNAs and improved the tube formation of HUVECs ([@ref21]). A study using EVs from CPC-Hpx (c-kit^＋^) reported the improvement of rat cardiac function and hypertrophy ([@ref14]). These imply that tube formation of CD90^low^c-kit^negative^ CMSC EVs under hypoxia was increased by triggering such signaling pathways. Further studies with our CD90^low^c-kit^negative^ CMSCs will add valuable insights on understanding the extracellular vesicular influence of these cells in hypoxic conditions. The clinical potential of EVs could greatly depend on the cell-culture environment. Further research is needed to examine how CMSCs under hypoxic conditions could produce more effective EVs. In earlier works, growth factors including HGF, VEGF, and bFGF were reported to be related to these functional differences between CDCs and MSCs ([@ref22]) and between the CD90^−^ and CD90^＋^ CDCs ([@ref12]). Since EVs have been reported to contain various growth factors, it is very likely that the more effective function of CMSC-Hpx EVs in our study resulted from the secretion of EVs with growth factors like HGF.

There are several questions to be answered by future research with EVs from CMSCs. First, the yield of EVs from CMSCs was lower than the yield of BM-MSC EVs ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). CMSC-EV tended to be more clingy, possibly because of the different nature of EVs, than were BM-MSC EVs, which may have caused unpredictable frequent loss during the EV isolation. Therefore, it was difficult to obtain sufficient EVs from CMSCs of our limited human samples. These technical problems should be solved for further experiments.

Second, the degree of tube formation was not increased in proportion to the concentration of EVs. Instead, the effect was best at the dose of 2 µg/ml (0.4 µg/well) of EVs in all three groups, but was decreased with a higher concentration of EVs ([Supplementary Fig. 2](#S1){ref-type="supplementary-material"}). There have been reports of biphasic results of tube augmentation with increasing concentration of EVs, although others demonstrated that angiogenesis increases dose-dependently with EVs treatment ([@ref21], [@ref39]). Additionally, they used ten times more EV concentration than were used in our work (25 µg/ml versus 2 µg/ml). These differences between different laboratories could have resulted for various technical reasons, such as different isolation methods, the purity of EVs, and different cell-culture environments. Controlling the detailed cell-culture condition and the standardized isolation methods of EVs are needed to solve the quality and quantity differences of EVs.

Our study showed that the hypoxic condition of CD90^low^c-kit^negative^ CMSCs could increase the secretion of EVs with active components for angiogenesis. These imply the functional importance of CD90^low^c-kit^negative^ CMSCs, which has often been underestimated in the CVD. Therefore, our results would help us understand the role of CD90^low^c-kit^negative^ cardiac cells and apply their EVs clinically to cardiac regeneration after CVD. Further investigations are needed to define the mechanism and the functional characterization of CMSC-Hpx EVs.

MATERIALS AND METHODS
=====================

Details are provided in the Supplementary materials.

Human CMSCs preparation
-----------------------

CMSCs were explanted from cadaveric tissue and expanded as described previously ([@ref25]). Briefly, after 14 d of dynamic tissue culture, outgrown cells were collected and suspended in growth-culture media for a conventional monolayer culture condition. When cells reached 80% confluence, they were detached and subcultured. Experiments were approved by the institutional review board of Busan Paik Hospital (IRB No. 2016-11-0006).
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![Characterization of the cells. (A) Flow cytometry results showed negative expression of CD117 and CD45, low expression of CD34, positive expression of CD105, and different expression of CD90 in the BM-MSCs and CMSCs. (B) RT-PCR analysis showed that the mRNA expression levels of NANOG, SOX2 in BM-MSCs, CMSC-Nx, and CMSC-Hpx were high, whereas the levels were hardly detectable for NKX2-4 and MYH6. The expression of GATA4 was detected only in CMSCs.](BMB-53-118-f1){#F1}

![Morphology and size of EVs. (A) Transmission electron microcopy showed about 100 nm of round EVs with a cup shape in each group. DLS analysis measured the size distributions (B) and the NTA demonstrated the high particle concentrations corresponding vesicle sizes, and the good purity (C).](BMB-53-118-f2){#F2}

![Purity analysis and markers for EVs. (A) Purity analysis by HPLC showed about 95% of elutes were within 5 min, which represented EV fractions in BMSCs and CMSCs. The small peak at 8 min contains substances with small molecular weight. (B) Immunoblotting analysis against EV surface markers, CD9, CD63, and CD81 on EV groups and whole cell lysates. H2B, histone, one of common contaminating substance in EV preparation, was not detected in all isolated EVs.](BMB-53-118-f3){#F3}

![Tube-formation assay of HUVECs treated with three types of EVs. (A) Microscopy images were taken for the tube-formation assay of HUVECs at 6 h. Endothelial growth media was used for a negative control (NC) and VEGF (20 ng/ml) was used for positive control; Cells were treated with media including EVs from BM-MSCs, CMSC-Nx, or CMSC-Hpx for experiments. Detailed methods are described in the [supplemental materials](#S1){ref-type="supplementary-material"}. (B) Total tube length at 6 h showed the augmented tube formation in the groups treated with VEGF, BM-MSC EVs, or CMSC-Hpx EVs; \*P \< 0.01, \*\*P \< 0.001 vs. NC, ns = no significance; ANOVA followed by Turkey post hoc analysis. (C) The tube-like structure was sustained until 8 h in VEGF and CMSC-Hpx EVs; \*P \< 0.05, \*\*P \< 0.01; student t-test within group at 6 h and 8 h.](BMB-53-118-f4){#F4}
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